NKGN (NKGen Biotech) Total Equity: $-50.33 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NKGen Biotech Total Equity?

NKGen Biotech NKGN Total Equity is $-50.33 Mil as of Mar. 2025.

NKGen Biotech's total equity for the quarter that ended in Mar. 2025 was $-50.33 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

NKGen Biotech Total Equity Historical Data

* Premium members only.

The historical data trend for NKGen Biotech's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech Total Equity Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Equity
-38.05 1.56 -58.69 -69.91

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.06 -69.72 -47.05 -69.91 -50.33

NKGen Biotech Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

NKGen Biotech's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=16.231-86.139
=-69.91

NKGen Biotech's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=15.842-66.174
=-50.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-50.33 Mil mean?
NKGen Biotech (NKGN) has a Total Equity of $-50.33 Mil as of Mar. 2025. The total amount of equity as record on a company's balance sheet. View historical data for NKGen Biotech and its competitors.
Is NKGen Biotech's Total Equity too high?
NKGen Biotech's current Total Equity is $-50.33 Mil.
How does NKGen Biotech's Total Equity compare to CALC and CLGN?
NKGen Biotech's Total Equity of $-50.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for NKGen Biotech and its competitors. NKGen Biotech's current Total Equity is $-50.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NKGen Biotech stock overvalued right now?
NKGen Biotech (NKGN) has a current Total Equity of $-50.33 Mil. The current Total Equity is $-50.33 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For NKGen Biotech (NKGN), the current Total Equity is $-50.33 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NKGen Biotech Business Description

Address 3001 Daimler Street, Santa Ana, CA, USA, 92705
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.